- PR Newswire•1 hour agoBenitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy
SYDNEY, Jan. 17, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that the European Commission, based on a favourable recommendation from the ...
- PR Newswire•25 days ago
Opportunity Analysis and Forecast to 2024, February 2016), approximately 64,000 new patients will be diagnosed annually in the US with HNSCC and 50% of the patients are expected to develop recurrent or metastatic disease, with approximately 13,000 annual deaths expected in the US from HNSCC.
- PR Newswire•28 days ago
SYDNEY, Dec. 20, 2016 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced significant progress on use of the company's technology for development of a ddRNAi ...
BLT.AX : Summary for BENITEC FPO - Yahoo Finance
Benitec Biopharma Limited (BLT.AX)
ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
|Day's Range||0.13 - 0.14|
|52 Week Range||0.09 - 0.30|
|PE Ratio (TTM)||-1.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|